Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with CD20 and CD22-positive, follicular or diffuse large B-cell NHL who have not responded or progressed after 1 or 2 prior therapies; or subjects with CD20 and CD22-positive intermediate/aggressive NHL (diffuse large B-cell, mantle cell, transformed follicular or follicular grade 3b NHL) who have not responded or progressed after 1 or more prior therapies and are refractory to a previous rituximab containing therapy.~* Prior therapy must contain at least one course of rituximab therapy, as single agent or in combination.~* Measurable disease.~Exclusion Criteria:~* Subjects who are candidates for other potentially curative therapies.~* Subjects must not have received previous radioimmunotherapy.~* Subjects who have undergone a prior bone marrow transplantation within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR) (Type: EXPERIMENTAL): Follicular
- INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL) (Type: EXPERIMENTAL): Diffuse Large B-cell Lymphoma
- INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY) (Type: EXPERIMENTAL): Refractory Aggressive NHL

Based on this trial design, predict the completion outcome and termination type (if applicable).